Drug developed by MD Anderson’s Therapeutics Discovery division is well-tolerated with effective glutaminase inhibition in Phase I trial The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division, appears to be well-tolerated […]
